Again FDA emphasises Importance of written Contracts
End 2016, the US Food and & Administration (FDA) published its long awaited final Guidance on Contract Manufacturer Quality Agreements.
The authority recommends that quality agreements should contain the following sections at a minimum:
- purpose and scope of the agreement
- terms of the agreement, including its effective dates
- terms for dispute resolution
- responsibility of each respective party
- change control and revision practices
And the agency takes things seriously. In a recent Warning Letter from March 2018, the FDA again refers to Quality Agreements and the respective guidance: "FDA is aware that many pharmaceutical product manufacturers use independent contractors, such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer." In their relationship with a customer, they recommend the addressee (Tris Pharma Inc.), to have a look at FDA's guidance document.
For further information please see the FDA Warning Letter to Tris Pharma Inc.
Related GMP News
25.06.2025Is Knowledge Management a Part of the Pharmaceutical Quality System?
11.06.2025Swissmedic differentiates GMP Scope for Manufacturing and Preparation for Administration
28.05.2025A View on the EU Critical Medicines Act to secure Pharma Supply Chains
20.05.2025Summary Data on Registration and Listing of Cosmetic Facilities and Products
07.05.2025FDA is extending its Quality Management Maturity Programme
30.04.2025FDA Warning Letter on missing Audit Trails and Raw Data Review